Danaher Co. (NYSE:DHR) SVP Sells $1,000,040.00 in Stock

Danaher Co. (NYSE:DHR) SVP Brian W. Ellis sold 4,000 shares of Danaher stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the transaction, the senior vice president now owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Danaher Trading Down 1.8 %

Shares of DHR traded down $4.59 during trading hours on Thursday, hitting $245.82. 2,943,521 shares of the stock were exchanged, compared to its average volume of 2,786,286. The firm has a market capitalization of $182.04 billion, a P/E ratio of 42.44, a price-to-earnings-growth ratio of 4.24 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00. The business has a 50-day moving average of $249.00 and a 200-day moving average of $230.78. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.48% and a net margin of 16.78%. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same period last year, the business posted $2.36 EPS. On average, research analysts expect that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is currently 18.31%.

Institutional Investors Weigh In On Danaher

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP grew its position in Danaher by 12.0% during the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after buying an additional 2,998,161 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Danaher by 10.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after purchasing an additional 1,619,586 shares in the last quarter. Capital International Investors grew its holdings in Danaher by 9.1% during the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after purchasing an additional 1,334,781 shares during the period. Bank of New York Mellon Corp increased its position in Danaher by 6.5% in the third quarter. Bank of New York Mellon Corp now owns 8,183,501 shares of the conglomerate’s stock worth $2,030,327,000 after buying an additional 502,868 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Danaher by 1.7% during the 3rd quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock valued at $2,009,789,000 after buying an additional 134,905 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada lifted their price objective on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. TD Cowen lifted their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday. Raymond James increased their price objective on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Robert W. Baird lifted their target price on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Citigroup increased their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday. Six research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $270.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.